Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion
- 21 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (5) , 741-749
- https://doi.org/10.1097/01.aids.0000216375.99560.a2
Abstract
Although HAART has led to a reduction in overall mortality among HIV-infected individuals, its impact on death from specific causes is unknown. Twenty-two cohorts of HIV-infected individuals with known dates of seroconversion are pooled in the CASCADE collaboration. Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes. The unknown causes were assigned a separate category. The cumulative incidence for each COD was calculated in the presence of the other competing COD, for the pre-HAART and HAART eras. A multivariate regression analyses for the cumulative rate of progression to the different COD was performed. A total of 1938 of 7680 HIV-seroconverters died. Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified. In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important. Large reductions in death due to other infections and organ failure were seen. Cumulative death risk decreased in the HAART era for most causes. The effect of HAART was not the same for all risk groups. The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU). A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs. Overall and cause specific mortality decreased following the introduction of HAART. OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future. Future trends in COD should be monitored using standardized guidelines.Keywords
This publication has 30 references indexed in Scilit:
- Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohortAIDS, 2005
- Determinants of survival following HIV-1 seroconversion after the introduction of HAARTThe Lancet, 2003
- Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 2003
- HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)Published by Elsevier ,2002
- Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study)The Journal of Infectious Diseases, 2002
- Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA studyAIDS, 2002
- Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths during 1995-1999Clinical Infectious Diseases, 2001
- Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual menAIDS, 2000
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- The progression of HCV‐associated liver disease in a cohort of haemophilic patientsBritish Journal of Haematology, 1994